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Summary A double-blind randomized crossover trial was performed to compare the antiemetic efficacy of two 5-HT3 receptor antagonists,
granisetron and ondansetron, in Chinese patients receiving adjuvant chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil) for
breast cancer. Twenty patients were randomized to receive chemotherapy with either granisetron on day 1 and ondansetron on day 8 of the
first cycle followed by the reverse order in the second cycle, or vice versa. The number of vomiting episodes and the severity of nausea in the
first 24 h (acute vomiting/nausea) and the following 7 days (delayed vomiting/nausea) were studied. Acute vomiting was completely
prevented in 29 (72.5%) cycles with granisetron and 27 (67.5%) cycles with ondansetron, and treatment failure (>5 vomiting episodes)
occurred in two (5%) cycles with each agent (P= NS). Acute nausea was completely controlled in 15 (37.5%) cycles with granisetron and 14
(35%) cycles with ondansetron, whereas severe acute nausea occurred in four (10%) cycles with each agent (P = NS). However, complete
response for delayed vomiting was observed in only 21 (52.5%) cycles with granisetron and 22 (55%) cycles with ondansetron (P= NS), and
delayed nausea was completely controlled in only 11 (27.5%) and ten (25%) cycles respectively (P= NS). In conclusion, both granisetron and
ondansetron are effective in controlling acute nausea and vomiting in Chinese patients, with equivalent antiemetic efficacy. Control of delayed
nausea and vomiting is less satisfactory.
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Nausea and vomiting are the most common side-effects of
chemotherapy. Traditional antiemetic agents such as metoclo-
pramide, anxiolytics and steroids have limited antiemetic efficacy.
5-HT3 receptor antagonists are a new class of more effective
antiemetic agents. Granisetron, ondansetron and tropisetron are
the currently available 5-HT3 receptor antagonists, and they differ
significantly in their pharmacokinetic properties such as
dose-response profile, receptor affinity, potency and duration of
action (Andrews et al, 1992). However, not until recently have
these agents been compared directly in their antiemetic efficacy in
randomized clinical trials.
Comparison ofgranisetron with ondansetron in Western studies
showed that the former had either equal or greater efficacy
(Jantunen et al, 1993; Gebbia et al, 1994; Noble et al, 1994; Ruffet
al, 1994; Navari et al, 1995; Mantovani et al, 1996). To our knowl-
edge, no study comparing these two agents in Oriental patients has
been reported before. Both drugs are mainly metabolized in the
liver by the cytochrome P450 enzymes (Bloomer et al, 1994;
Fischer et al, 1994). Ethnic differences in drug metabolism by the
cytochrome P450 enzymes between Caucasians and Orientals are
well recognized (Kalow, 1982; Vetticaden, 1988; Relling, 1989;
Johansson et al, 1994). A clinical trial was performed to compare
the antiemetic efficacy of granisetron and ondansetron in Chinese
patients.
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MATERIALS AND METHODS
Study design
A prospective double-blind randomized crossover trial was carried
out in 20 consecutive female patients receiving adjuvant
chemotherapy after resection ofbreast cancer. None ofthe patients
had had chemotherapy before and none had brain or gastro-
intestinal diseases that might lead to nausea or vomiting. All
patients had normal liver and renal function. The chemotherapy
regimen consisted of six monthly cycles of cyclophosphamide
(500 mg m-2 i.v.), methotrexate (40 mg m-2 i.v.) and 5-fluorouracil
(500 mg m-2 i.v.) given on day 1 and day 8 ofeach cycle. The first
two cycles of chemotherapy for each patient were used for the
trial. Patients were randomized to receive chemotherapy with
either granisetron on day 1 followed by ondansetron on day 8 in
the first cycle, or ondansetron on day 1 followed by granisetron on
day 8. The two drugs were then given in the reverse order in the
second cycle. Single-dose granisetron 3 mg i.v. was given just
before starting the chemotherapy. Ondansetron was given in two
doses: 8 mg i.v. before the chemotherapy followed by 8 mg i.v. 8 h
later. Informed consent was obtained before entry into the trial.
Neither the patients nor the investigators knew the exact
antiemetic agent used in each treatment. No concomitant treatment
with other antiemetic drugs was given.
Methods of assessment
The number ofvomiting episodes in the first 24 h (acute vomiting)
and the following 7 days (delayed vomiting) after each
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Table 1 Effects of granisetron and ondansetron on acute vomiting and
nausea
Response Granisetron Ondansetron P-value
No. of treatment cycles 40 40
Acute vomiting
Complete response 29 (72.5%) 27 (67.5%) NS
Major response 6 (15%) 9 (22.5%) NS
Minor response 3 (7.5%) 2 (5%) NS
Failure 2 (5%) 2 (5%) NS
Acute nausea
No nausea 15 (37.5%) 14 (35%) NS
Mild nausea 15 (37.5%) 18 (45%) NS
Moderate nausea 6 (15%) 4 (10%) NS
Severe nausea 4 (10%) 4 (10%) NS
Mean VAS score (range) 2.2 (0-9) 2.5 (0-8) NS
NS, not significant.
Table 2 Effects of granisetron and ondansetron on delayed vomiting and
nausea
Response Granisetron Ondansetron P-value
No. of treatment cycles 40 40
Delayed vomiting
Complete response 21 (52.5%) 22 (55%) NS
Major response 8 (20%) 7 (17.5%) NS
Minor response 7 (17.5%) 6 (15%) NS
Failure 4 (10%) 5 (12.5%) NS
Delayed nausea
No nausea 11 (27.5%) 10 (25%) NS
Mild nausea 16 (40%) 21 (52.5%) NS
Moderate nausea 9 (47.5%) 6 (15%) NS
Severe nausea 4 (10%) 3 (7.5%) NS
Mean VAS score (range) 2.9 (0-9) 2.8 (0-9) NS
NS, not significant.
chemotherapy treatment was recorded. The antiemetic efficacy
was classified as follows: complete response, no vomiting; major
response, 1-2 vomiting episodes; minor response, 3-5 vomiting
episodes; and failure, more than five vomiting episodes. Nausea in
the first 24 h (acute nausea) and the following 7 days (delayed
nausea) was assessed by both a graded scale and a visual analogue
scale. In the graded scale, patients indicated the severity ofnausea
in one offour grades: none, no nausea; mild, interfere with eating;
moderate, interfere with daily life; and severe, bedridden because
of nausea. In the visual analogue scale (VAS), patients indicated
the severity of nausea on a scale of 0 (no nausea) to 10 (worst
nausea ever experienced).
Statistical analysis
Data are reported as relative frequencies (%). Statistical analysis
was performed using the chi-square test (or Fisher's exact test
when appropriate) for nominal variables and Student's t-test for
numerical variables. Statistical significance was when P < 0.05.
RESULTS
The median age of the patients was 47 years (range 37-74 years).
Eighteen patients had modified radical mastectomy and two had
wide local excision plus axillary dissection. It was planned that the
latter two patients would have ipsilateral breast irradiation as a
'sandwiched' course after the first two cycles of chemotherapy
and hence no irradiation was given before or during the trial. All
patients received CMF chemotherapy 2-3 weeks after resection of
the breast cancer. Granisetron and ondansetron were each used in
40 treatment cycles (20 day-I and 20 day-8 chemotherapy).
Acute vomiting and nausea
There was no significant difference between the two drugs in the
efficacy of preventing acute vomiting (Table 1). Major efficacy
(complete or major response) was achieved in 35 (87.5%) cycles
with granisetron and 36 (90%) cycles with ondansetron (P = NS).
The efficacy of the two drugs on acute nausea was not signifi-
cantly different either (Table 1). Major efficacy (no nausea or
minor nausea) was observed in 30 (75%) cycles with granisetron
and 32 (80%) cycles with ondansetron (P = NS). The mean VAS
score was not significantly different (Table 1).
Delayed vomiting and nausea
The two drugs had similar efficacy for delayed vomiting (Table 2).
Major efficacy was achieved in 29 (72.5%) cycles with each drug.
For prophylaxis ofdelayed nausea, majorefficacy was observed in
27 (67.5%) cycles with granisetron and 31 (77.5%) cycles with
ondansetron (P = NS) (Table 2). The mean VAS score was similar
(Table 2).
Side-effects
No serious side-effects were observed. The most common side-
effect was constipation, which occurred more frequently with
ondansetron (30%) than granisetron (20%) (P = NS). Headache
was also more common with ondansetron (25%) than granisetron
(20%) (P = NS).
DISCUSSION
Jantunen et al (1993) reported the first randomized trial comparing
the 5-HT3 receptor antagonists in patients receiving moderately
emetogenic chemotherapy and found a significantly higher
complete response and lower failure rates in controlling acute
vomiting with granisetron 3 mg i.v. single dose than with
ondansetron 8 mg i.v. single dose. Five subsequent randomized
trials showed no significant difference in the antiemetic efficacy
between intravenous granisetron and ondansetron (Gebbia et al,
1994; Noble et al, 1994; Ruff et al, 1994; Navari et al, 1995;
Mantovani et al, 1996). These studies compared the two agents in
patients receiving cisplatin-based highly emetogenic regimens,
except for the study of Gebbia et al (1994), which also included a
comparison of the two agents in moderately emetogenic
chemotherapy. Apart from the study by Mantovani et al (1996),
which comprised mainly male patients with head and neck cancers
receiving cisplatin-based regimens, the other studies were carried
out in heterogeneous groups of patients of both sexes with
different types of cancer receiving different chemotherapy regi-
mens. Variations in patient and treatment characteristics might
have significant effects on the results of the studies. For example,
nausea and vomiting have been reported to be more severe and
frequent in women regardless of cancer site or antiemetic treat-
ment (Tonato et al, 1991).
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The patients in this study were a very homogeneous group ofthe
same sex receiving the same chemotherapy regimen for adjuvant
treatment ofbreast cancer. This minimized variations in patient and
treatment characteristics. The CMF regimen allowed crossover of
the two antiemetic drugs within the same cycle in the same patient,
and the reverse crossover during the second cycle eliminated any
influence on the results caused by a possible residual effect of day-
1 antiemetic agent on day-8 treatment. Our results showed that
there was no significant difference in the antiemetic efficacy for
acute or delayed nausea and vomiting between one dose of
granisetron i.v. 3 mg and two doses of ondansetron i.v. 8 mg in
Chinese patients. The complete response rate for acute vomiting
was 72.5% with granisetron and 67.5% with ondansetron, similar to
figures in the two Western trials with moderately emetogenic
chemotherapy (Jantunen et al, 1993; Gebbia et al, 1994). Both
drugs were well tolerated by Chinese patients.
The control ofdelayed nausea and vomiting was less satisfactory.
The major efficacy rate in preventing acute vomiting was 87.5% for
granisetron and 90% for ondansetron, whereas the major efficacy
rate for delayed vomiting was only 72.5% for both agents. The aeti-
ology of delayed nausea and vomiting is unknown but is probably
multifactorial (Andrew and Davis, 1993). It generally lasts up to 7
days post treatment and is difficult to control with conventional
antiemetic therapy (Kris et al, 1985). The unsatisfactory control
even with 5-HT3 receptor antagonists necessitates the search for
more effective antiemetic regimens. There is evidence that a combi-
nation of 5-HT3 receptor antagonists with dexamethasone was
superior to 5-HT3 receptor antagonists alone (Roila et al, 1991).
As the two 5-HT3 receptor antagonists have equivalent
antiemetic efficacy, cost may become an important consideration
in the choice ofagent. In our institute, the cost for one hospitalized
patient per treatment of one dose ofgranisetron i.v. 3 mg was half
that of two doses of ondansetron i.v. 8 mg. However, the cost of
ondansetron will vary with the dosage used and the optimal dosage
regimen for ondansetron has not been fully clarified. The issue is
further complicated by the availability of an oral preparation of
ondansetron, which is not yet available for granisetron. Two
randomized clinical trials have compared intravenous granisetron
with intravenous plus oral ondansetron and found similar efficacy
(Bonneterre and Hecquet, 1994; Stewart et al, 1995). The efficacy
of oral ondansetron regimens requires further investigation.
In conclusion, our study shows that both intravenous
granisetron and intravenous ondansetron are highly effective in
controlling acute nausea and vomiting induced by moderately
emetogenic chemotherapy in Chinese patients and they have
equivalent antiemetic efficacy. Control of delayed nausea and
vomiting is less satisfactory. Further studies are needed to find out
the optimal antiemetic regimens for chemotherapy.
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